DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds
DBV Technologies to Participate in Upcoming November Investor Conferences
Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46
Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47
DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss
DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
DBV Technologies Q3 2026 Earnings Call Transcript
DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.